focusing on quality patient care in the new global subsidy for malaria medicines关注病人护理质量在新的全球疟疾药物补贴.pdfVIP

Policy Forum Focusing on Quality Patient Care in the New Global Subsidy for Malaria Medicines 1 ´ 2 3 3 Suerie Moon , Carmen Perez Casas , Jean-Marie Kindermans , Martin de Smet , Tido von Schoen- Angerer2* 1 Giorgio Ruffolo Doctoral Research Fellow, Sustainability Science Program, Center for International Development, Kennedy School of Government, Harvard University, ´ ` ´ Cambridge, Massachusetts, United States of America, 2 Campaign for Access to Essential Medicines, Medecins Sans Frontieres, Geneva, Switzerland, 3 Medecins Sans ` Frontieres, Brussels, Belgium Introduction Box 1. The Affordable Medicines Facility–malaria (AMFm) Almost 40 years ago, Chinese scientists rediscovered the near-miraculous potency The Affordable Medicines Facility–malaria (AMFm), a new global health initiative, of artemisinin derivatives against malaria. aims to address inadequate access to ACT for treating P. falciparum malaria by Today, we are approaching a decade since subsidizing producer prices. First proposed in 2004 [33], the facility is expected to the World Health Organization (WHO) begin operating in late 2009. Resistance to older antimalarial drugs such as CQ or recommended that artemisinin-based SP is now widespread, making ACTs the most effective treatment for P. combination therapies (ACTs) replace falciparum, the deadliest variant of malaria; however, ACTs cost 10 to 20 times as older antimalarials rendered inef